The Technical AnalystExchange: ASX Industry: Pharmaceuticals, Biotechnology & Life Sciences
Invex Therapeutics Ltd Price, Forecast, Insider, Ratings, Fundamentals & Signals
-2.44% $0.0800
America/New_York / 2 mai 2024 @ 01:34
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 6.01 mill |
| EPS: | -0.0800 |
| P/E: | -1.000 |
| Earnings Date: | Feb 16, 2024 |
| SharesOutstanding: | 75.15 mill |
| Avg Daily Volume: | 0.0440 mill |
| RATING 2024-05-02 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 4/23 | |
| Revenue | n/a | n/a | ||||
| Gr.Profit | n/a | |||||
| Ebit | n/a | |||||
| Asset | n/a | n/a | n/a | n/a | ||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.000 | sector: PE 1.258 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.03x |
| Company: PE -1.000 | industry: PE 38.27 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0760 - 0.0840 ( +/- 5.00%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.0800 (-2.44% ) |
| Volume | 0.0070 mill |
| Avg. Vol. | 0.0440 mill |
| % of Avg. Vol | 15.88 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For IXC.AX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
IXC.AX
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II clinical trial. The company was incorporated in 2019 and is based in Perth, Australia.